EHMT2 and diffuse large B-cell lymphoma: Niclosamide demonstrates the ability to (1) inhibit G9a expression, (2) modulate autophagy-related genes, and (3) suppress the growth of DLBCL cells, signifying a novel therapeutic direction for DLBCL treatment by targeting G9a modulation and highlighting the potential of niclosamide as a pharmacological intervention for DLBCL.